Example: Heart Attack

Search clinical trials for: Mitoxantrone

Total 300 results

NCT04486391

Not yet recruiting

Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma

Conditions: Classical Hodgkin Lymphoma
NCT04375631

Not yet recruiting

CLAG-M Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

Conditions: Recurrent Acute Myeloid Leukemia; Recurrent Chronic Myelomonocytic Leukemia; Recurrent Myelodysplastic Syndrome; Refractory Acute Myeloid Leukemia; Refractory Chronic Myelomonocytic Leukemia; Refractory Mixed Phenotype Acute Leukemia; Refractory Myelodysplastic Syndrome; Refractory Acute Leukemia of Ambiguous Lineage; Refractory Acute Undifferentiated Leukemia
NCT04352413

Recruiting

A Study of PLM60 in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based First-Line Chemotherapy

Conditions: Small Cell Lung Cancer
NCT04330820

Recruiting

Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX)

Conditions: Relapsed Adult AML
NCT04331743

Not yet recruiting

A Study to Evaluate the Safety and Efficacy of PLM60 in Advanced HCC

Conditions: Advanced Hepatocellular Carcinoma
NCT04293562

Recruiting

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Conditions: Acute Myeloid Leukemia
NCT04195945

Recruiting

CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients

Conditions: Acute Myeloid Leukemia; Myeloid Neoplasm
NCT04196010

Recruiting

Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms

Conditions: Myeloid Neoplasm; Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia
NCT04024241

Recruiting

Medium Dose of Cytarabine and Mitoxantrone

Conditions: Acute Myelogenous Leukemia; Chemotherapy
NCT03989713

Not yet recruiting

Quizartinib and High-dose Ara-C Plus Mitoxantrone in Relapsed/Refractory AML With FLT3-ITD

Conditions: AML According to WHO 2016 Classification (Except Acute Promyelocytic Leukemia), Refractory to Induction Therapy or Relapsed After First Line Treatment
NCT03983824

Recruiting

Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia

Conditions: Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia
NCT03926624

Recruiting

Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd Salvage

Conditions: Leukemia, Myeloid, Acute
NCT03882203

Recruiting

CLAME Sequential With Flu-Bu Conditioning for Refractory Acute Leukemia

Conditions: Refractory Hematologic Cancer; Allogeneic Stem Cell Transplantation
NCT03860844

Recruiting

Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

Conditions: Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia
NCT03839446

Recruiting

Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy

Conditions: Acute Myeloid Leukemia
NCT03776279

Recruiting

A Study of Liposome-entrapped Mitoxantrone Hydrochloride Injection in Relapsed/Refractory Peripheral T-cell Lymphoma and NK/T-cell Lymphoma

Conditions: Relapsed or Refractory Peripheral T-cell and NK/T-cell Lymphoma
NCT03735446

Terminated

Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial

Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndromes
NCT03616470

Recruiting

Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia

Conditions: Acute Myeloid Leukemia
NCT03591510

Suspended

A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML

Conditions: FLT3-mutated Acute Myeloid Leukemia
NCT03576378

Recruiting

BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL)

Conditions: Hodgkin Lymphoma
NCT03563560

Active, not recruiting

A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid Leukemia

Conditions: Acute Myeloid Leukemia
NCT03531918

Recruiting

Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine and Mitoxantrone in Treating Participants With Previously Untreated Acute Myeloid Leukemia or High-Grade Myeloid Neoplasm

Conditions: Acute Myeloid Leukemia; High-Grade Myeloid Neoplasm; Blasts 10 Percent or More of Bone Marrow Nucleated Cells; Blasts 10 Percent or More of Peripheral Blood White Cells; High Grade Myeloid Neoplasm
NCT03504410

Recruiting

Study Evaluating Efficacy and Safety of CPI-613 in Combination With HD Cytarabine and Mitoxantrone Compared to HD Cytarabine and Mitoxantrone and Control Sub-groups: MEC and FLAG in Older Patients With R/R AML

Conditions: Relapsed/Refractory Acute Myeloid Leukemia
NCT03441048

Recruiting

Lintuzumab-Ac225 in Combination With CLAG-M Chemotherapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Conditions: Acute Myeloid Leukemia
NCT03258320

Recruiting

A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients Without Metastasis

Conditions: Prostate Cancer Patients
NCT03257241

Recruiting

A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients ≤ 60 Years Old

Conditions: Acute Myeloid Leukemia
NCT03250338

Recruiting

Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML

Conditions: Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
NCT03182244

Recruiting

A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation

Conditions: Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
NCT03173612

Recruiting

The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid Leukemia

Conditions: Acute Myeloid Leukemia
NCT03165851

Completed

Efficacy Analysis of Comparison of CAMS（Chinese Academy of Medical Sciences）-2005 Trial and CAMS-2009 Trial for Pediatric Acute Myeloid Leukemia

Conditions: Acute Myeloid Leukemia, Pediatric
NCT03164057

Recruiting

A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia

Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndromes
NCT03150004

Recruiting

Efficacy and Pharmacogenomics of Salvage CLAG-M Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia

Conditions: Acute Myeloid Leukemia
NCT03118466

Recruiting

Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia

Conditions: AML
NCT03026842

Active, not recruiting

Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Acute Myeloid Leukemia With t(8;21)

Conditions: Acute Myeloid Leukemia
NCT03012672

Recruiting

Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm

Conditions: Acute Leukemia of Ambiguous Lineage; Acute Myeloid Leukemia; Myeloid Neoplasm
NCT02937285

Active, not recruiting

National Multicenter, Controlled, Single-blind Study With Two Parallel Groups Evaluating the Safety and Efficacy of Sequential Treatment With Mitoxantrone and Interferon Versus Interferon Alone in Patients With Strong Risk of Progression in the Initial Phase of Multiple Sclerosis

Conditions: Multiple Sclerosis
NCT02921061

Completed

Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS

Conditions: Mixed Phenotype Acute Leukemia; Previously Treated Myelodysplastic Syndrome; Recurrent Adult Acute Myeloid Leukemia; Recurrent High Risk Myelodysplastic Syndrome; Refractory Acute Myeloid Leukemia; Refractory High Risk Myelodysplastic Syndrome; Untreated Adult Acute Myeloid Leukemia
NCT02910752

Recruiting

CLAM Chemotherapy With PBSC Support for Relapsed Patients After Allogeneic Stem Cell Transplantation

Conditions: Leukemia
NCT02907359

Active, not recruiting

Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs

Conditions: Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic
NCT02879643

Recruiting

Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapsed ALL

Conditions: ALL, Childhood; Lymphoblastic Leukemia, Acute, Childhood; Lymphoblastic Leukemia, Acute
NCT02856685

Unknown status

A Study of Mitoxantrone Hydrochloride Liposome Infusion

Conditions: Non-Hodgkin's Lymphoma
NCT02848183

Recruiting

Optimal Treatment Strategy Based on for Pediatric AML

Conditions: Pediatric Acute Myeloid Leukemia
NCT02788201

Completed

Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma

Conditions: Urothelial Carcinoma; Bladder Cancer; Urinary Bladder Neoplasms
NCT02756572

Completed

Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms

Conditions: Blasts 10 Percent or More of Bone Marrow Nucleated Cells; Chronic Myelomonocytic Leukemia-2; High Grade Malignant Neoplasm; Myelodysplastic Syndrome; Myelodysplastic Syndrome With Excess Blasts-2; Myeloid Neoplasm; Previously Treated Myelodysplastic Syndrome; Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia
NCT02733380

Recruiting

Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma

Conditions: Diffuse Large B-cell Lymphoma
NCT02728050

Recruiting

Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib Tosylate in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Conditions: Acute Biphenotypic Leukemia; Acute Myeloid Leukemia; de Novo Myelodysplastic Syndrome; Myelodysplastic Syndrome; Myeloproliferative Neoplasm
NCT02724163

Recruiting

International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia

Conditions: Acute Myeloid Leukaemia
NCT02688140

Recruiting

Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia

Conditions: Acute Promyelocytic Leukemia
NCT02687386

Recruiting

A Study of Intravenous EEDVsMit in Children With Recurrent / Refractory Solid or CNS Tumours Expressing EGFR

Conditions: Solid Tumours; CNS Tumours
NCT02686593

Completed

Clofarabine, Cytarabine and Mitoxantrone (CLAM) for Relapsed or Refractory AML

Conditions: Acute Myeloid Leukemia